Format

Send to

Choose Destination
Drug Discov Today. 2007 Mar;12(5-6):209-17. Epub 2007 Feb 5.

Emerging host cell targets for hepatitis C therapy.

Author information

1
Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA. yupeng.he@abbott.com

Abstract

Chronic hepatitis C virus (HCV) infection is a major burden on humanity. The current HCV therapy has limited efficacy, and there is pressing need for new and more effective therapies. Host cell factors that are required for HCV infection, replication and/or pathogenesis represent potential therapeutic targets. Of particular interest are cellular receptors that mediate HCV entry, factors that facilitate HCV replication and assembly, and intracellular pathways involving lipid biosynthesis, oxidative stress and innate immune response. A crucial challenge now is to manipulate such cellular targets pharmacologically for chronic HCV treatment, without being limited by side effects.

PMID:
17331885
DOI:
10.1016/j.drudis.2007.01.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center